ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer identifier:
NCT04267939 (

Advanced ovarian cancer or other solid tumors

Study Contact Information:

For additional information, contact: Bayer Clinical Trials by phone: 1-888-842-2937 or by email 

About the Study

This study will look at how well how people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib. This study is open to participants who have had their ovarian cancer progress while on a PARP inhibitor. 

Type of Study

This is an open-label, single group study. All participants will receive the same medications. 

What the Study Entails

Study participants will be placed into one of three groups based on their situation.

All study participants will receive the following:

Study participants will be followed for up to 24 months.

Study Sites

Boston, MA
Dana-Farber Cancer Institute

New York
New York, NY
Memorial Sloan-Kettering Cancer Center

Cleveland Clinic

MD Anderson Cancer Center

This Study is Open To:

People age 18 years and older can be considered for enrollment in this study if they:


This Study is Not Open To:

People cannot participate if they have any of the following:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.